Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5Prostate Adenocarcinoma 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Lymphatic Metastasis 1Carcinoma, Renal Cell 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Nivolumab 37pembrolizumab 30cabozantinib 27Specimen Handling 25Magnetic Resonance Spectroscopy 22Ipilimumab 20lenvatinib 16Axitinib 15belzutifan 13CTLA-4 Antigen 10Sunitinib 9Biopsy 9Radiosurgery 8atezolizumab 7Immunoglobulin G 5toripalimab 4fludarabine 4avelumab 4aldesleukin 4Everolimus 4Disulfides 4Cyclophosphamide 4zimberelimab 3tivozanib 3spartalizumab 3pazopanib 3palbociclib 3durvalumab 3cemiplimab 3X-Rays 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × radium Ra 223 dichloride × 90 days × Clear all
NCT04071223 2026-05-13

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

National Cancer Institute (NCI)

Phase 2 Active not recruiting
134 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡